Rare eye diseases are the leading cause of untreatable blindness in Europe and affect people of all ages. The RESTORE VISION ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

The trial found that mastic was effective in controlling the symptoms of 80pc of individuals with duodenal ulcers. Just two weeks of mastic treatment led to complete ulcer healing in 70pc of ...

Philip Cheung for The New York Times Supported by By Moises Velasquez ... But recently he had developed an abscess at an injection site on his leg. Now he was in Highland Hospital, in Oakland ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous leg ulcers (VLUs ... either the therapy or a placebo.

Here Dr. Usmani discusses the current outlook for the disease and his vision for developing new treatment approaches at MSK that will improve multiple myeloma prognosis (outcome). This includes very ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The ...

12, 2025 – The FDA has approved a new pill for a rare genetic disorder ... It’s the first treatment approved for both adults and children with NF1-related tumors. The FDA’s decision ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The company said its EscharEx treatment had previously demonstrated its ability to effectively and ...